These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 35708709)
1. Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial. Wang X; Zhang L; Liu X; Li X; Li L; Fu X; Sun Z; Wu J; Zhang X; Yan J; Chang Y; Nan F; Zhou Z; Wu X; Tian L; Ma M; Li Z; Yu H; Zhu L; Wang Y; Shi C; Feng X; Li J; Ding M; Zhang J; Dong M; Xue H; Wang J; Zou L; Su L; Wu J; Liu L; Bao H; Zhang L; Guo Y; Guo S; Lu Y; Young KH; Li W; Zhang M JAMA Oncol; 2022 Jul; 8(7):1035-1041. PubMed ID: 35708709 [TBL] [Abstract][Full Text] [Related]
2. DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China. Li X; Cui Y; Sun Z; Zhang L; Li L; Wang X; Wu J; Fu X; Ma W; Zhang X; Chang Y; Nan F; Li W; Su L; Wang J; Xue H; Zhang M Clin Cancer Res; 2016 Nov; 22(21):5223-5228. PubMed ID: 27060152 [TBL] [Abstract][Full Text] [Related]
3. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients. Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149. Zhang L; Jia S; Ma Y; Li L; Li X; Wang X; Fu X; Ma W; Qin Y; Li W; Wu J; Sun Z; Zhang X; Nan F; Chang Y; Li Z; Zhang D; Wang G; Yan J; Su L; Wang J; Xue H; Young KH; Zhang M Oncotarget; 2016 Aug; 7(34):55721-55731. PubMed ID: 27384676 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients. Zhou Z; Li X; Chen C; Li X; Zhang L; Li L; Wang X; Ma W; Fu X; Wu J; Sun Z; Zhang X; Li Z; Yan J; Chang Y; Lu L; Qin B; Li X; Wen J; Zhang M Ann Hematol; 2014 Nov; 93(11):1889-94. PubMed ID: 24923454 [TBL] [Abstract][Full Text] [Related]
6. The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type. Zhang L; Li S; Jia S; Nan F; Li Z; Cao J; Fan S; Zhang C; Su L; Wang J; Xue H; Zhang M Oncotarget; 2016 Sep; 7(36):58396-58404. PubMed ID: 27517317 [TBL] [Abstract][Full Text] [Related]
7. Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter study. Zhang L; Wang Y; Li X; Li L; Wang X; Sun Z; Wu J; Fu X; Zhang X; Yu H; Wang G; Chang Y; Yan J; Zhou Z; Wu X; Nan F; Li W; Zhang M Int J Cancer; 2021 Mar; 148(6):1470-1477. PubMed ID: 33034052 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma. Li L; Zhang C; Zhang L; Li X; Wu JJ; Sun ZC; Fu XR; Wang XH; Chang Y; Wang R; Qiu YJ; Zhang MZ Neoplasma; 2014; 61(2):225-32. PubMed ID: 24299319 [TBL] [Abstract][Full Text] [Related]
9. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study. Wei C; Cao X; Zhang W; Zhang Y; Wang W; Zhang L; Yang C; Feng J; Cai H; Chen M; Mao Y; Zhou D Ann Hematol; 2020 Dec; 99(12):2801-2809. PubMed ID: 32399707 [TBL] [Abstract][Full Text] [Related]
10. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma. Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393 [TBL] [Abstract][Full Text] [Related]
12. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Yamaguchi M; Suzuki R; Kwong YL; Kim WS; Hasegawa Y; Izutsu K; Suzumiya J; Okamura T; Nakamura S; Kawa K; Oshimi K Cancer Sci; 2008 May; 99(5):1016-20. PubMed ID: 18294294 [TBL] [Abstract][Full Text] [Related]
13. DDGP followed by radiotherapy vs VIPD followed by radiotherapy in newly diagnosed early NK/T-cell lymphoma. Zhang L; Shangguan C; Li X; Li L; Wang X; Fu X; Sun Z; Shi Y; Wu J; Zhang X; Yu H; Nan F; Yan J; Chang Y; Zhou Z; Wu X; Feng X; Liu X; Xue H; Zou L; Lu Y; Wang J; Wang G; Li W; Zhang M Leuk Res; 2022 Jul; 118():106881. PubMed ID: 35688096 [TBL] [Abstract][Full Text] [Related]
14. First-line LVDP (L-asparaginase, etoposide, dexamethasone, and cisplatin) regimen combined with radiotherapy is effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type. Wu W; Chen X; Li N; Luo Q; Zou L Ann Hematol; 2022 Jul; 101(7):1557-1565. PubMed ID: 35585247 [TBL] [Abstract][Full Text] [Related]
15. Treatment and Prognosis of Newly Diagnosed Advanced-Stage Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Real-World Study across Two Decades. Wei YC; Qi F; Chen B; Zhang CG; Fang H; Zhang D; Qi SN; Chai Y; Li YX; Dong M Chemotherapy; 2024; 69(2):108-121. PubMed ID: 37984344 [TBL] [Abstract][Full Text] [Related]
17. Comparative Study of L-Asparaginase-Based LOP Regimen Over CHOP Regimen Before Radiotherapy for Stage IIE Extranodal Nasal Type NK/T Cell Lymphoma: A Study of 2 Centers. Huang L; Yuan B; Wu H; Chu H; Liu Y; Wu S; Li H; Lu H; Chen H Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):152-158. PubMed ID: 28215935 [TBL] [Abstract][Full Text] [Related]
18. First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial. Tian XP; Cai J; Xia Y; Zhang YC; Wang L; Liu PP; Huang HQ; Li YJ; Zhou H; Li ZM; Yang J; Wei LQ; Zou QH; Huang Y; Li J; Ling L; Zhong WL; Cai QQ Lancet Haematol; 2024 May; 11(5):e336-e344. PubMed ID: 38554717 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the clinical efficacies of two L-asparaginase-based chemotherapy regimens for newly diagnosed nasal-type extranodal NK/T-cell lymphoma. Wu W; Ren K; Chen X; Li N; Luo Q; Hai T; Zhou H; Zou L Cancer Med; 2023 Apr; 12(8):9458-9470. PubMed ID: 37000008 [TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III-IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus. Zhao Q; Fan S; Chang Y; Liu X; Li W; Ma Q; Li Y; Wang Y; Zhang L; Zhang M Cancer Manag Res; 2019; 11():3555-3564. PubMed ID: 31118779 [No Abstract] [Full Text] [Related] [Next] [New Search]